- Mankind Pharma's consolidated net profit rose 29% to Rs 574.09 crore in Q1 FY27
- Revenue increased 12.9% year-on-year to Rs 4,031 crore in the quarter ended June
- Ebitda grew 24.9% to Rs 1,057 crore with margin rising to 26.2% from 23.7% last year
Mankind Pharma Ltd. reported a 29% year-on-year rise in its consolidated net profit for the quarter ended June, while revenue crossed Rs 4,000 crore.
The company posted a consolidated net profit of Rs 574.09 crore in the June quarter, compared with Rs 444.62 crore in the corresponding quarter last year. Revenue from operations increased by 12.9% year-on-year to Rs 4,031 crore, against Rs 3,570 crore reported in the year-ago period, according to an exchange filing on Thursday.
Earnings before interest, tax, depreciation and amortisation (Ebitda) rose 24.9% to Rs 1,057 crore, compared with Rs 846 crore in the same quarter last year. The company's Ebitda margin improved to 26.2% in the first quarter of fiscal 2027, up from 23.7% a year earlier.
Mankind Pharma shares closed 0.88% lower at Rs 2,569.9 per share on the NSE against a 0.28% climb in the benchmark Nifty 50 on Thursday.
ALSO READ: Vedanta Q1 Results: Profit Slumps 18% Even As Margin Expands; Revenue Declines
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.